HERE Technologies deepens collaboration with China’s intelligent driving innovator neueHCT to accelerate global NOA expansion
CTF Life Launches MyWealth Beyond Savings Insurance Plan
6 Ways to Avoid Hidden Fees When Spending Overseas
China Chunlai Announces 2026 Interim Results
FREELANDER 8 Production-Intent Show Model Makes Global Debut: First Complete Look at the Legend Reborn
Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1…
ERAS-601, a potential best-in-class SHP2 inhibitor, blocks oncogenic signal transduction to delay onset of therapeutic…
ERAS-601, a potential best-in-class SHP2 inhibitor, blocks oncogenic signal transduction to delay onset of therapeutic…
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in…
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in…
Data presented at AACR Annual Meeting support IMM-1-104’s potential to address a broad population of…
Data presented at AACR Annual Meeting support IMM-1-104’s potential to address a broad population of…
Preclinical data suggests that sudocetaxel zendusortide can induce immune cell infiltration in “cold” tumors and…
Preclinical data suggests that sudocetaxel zendusortide can induce immune cell infiltration in “cold” tumors and…
Data demonstrated D-4559 switches tumor associated macrophages from an M2 to M1 pro-inflammatory phenotype leading…
Data demonstrated D-4559 switches tumor associated macrophages from an M2 to M1 pro-inflammatory phenotype leading…
– 100% accuracy predicting clinical responders with Notable’s PPMP with enhanced machine learning – – Fourth clinical…
– 100% accuracy predicting clinical responders with Notable’s PPMP with enhanced machine learning – – Fourth clinical…
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing…
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing…
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)…
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)…
ORLANDO, Fla., April 18, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a fully integrated biopharmaceutical…
ORLANDO, Fla., April 18, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a fully integrated biopharmaceutical…
Qualigen Therapeutics, Inc. Abstract #4981 Qualigen Therapeutics, Inc. Abstract #6240 CARLSBAD, Calif., April 18, 2023…